BREAKTHROUGH NANO LIPOSOME-BOUND TECHNOLOGY TO TREAT LOCALIZED CANCER TUMORS
LIPAC Oncology is a clinical-stage company with the very first precision targeted, locally delivered taxane technology platform. Its growing pipeline targets areas of great unmet need in Bladder Cancer, Malignant Pleural Effusion (MPE), Upper Tract Urothelial Carcinoma, Stage II/III Ovarian Cancer, and Intraperitoneal Carcinoma.
Find out about our organization, team, and the results of our decades of research and development
Explore the pipeline of new products we are developing and taking into the clinic